Get the content you want anytime you want.

Top 5 Contagion® News Articles for the Week of March 19, 2017

This week’s Top 5 articles focused on multiple infectious diseases, such as human papilloma virus (HPV), a sexually transmitted disease for which a new 2-dose regimen has recently been found to be just as effective as the typical 3-dose regimen for some populations. In addition, researchers have found that obesity and heart failure can have a negative impact on the effectiveness of antibiotic regimens for some skin and soft tissue infections. Along the same vein as skin and soft tissue infections, we published an article on the pervasiveness of Staphylococcus aureus skin infections in professional sports. Finally, a new report on the potential for the 2016-2017 flu season to last until May for parts of the United States and an article on the importance of disinfectants in the era of the “superbug” round out our top two articles for the week.

#5: Updated HPV Vaccine Recommendations Include 2 Doses for Some, 3 for Others 

Sexually transmitted diseases continue to be an issue around the world and so methods to treat and prevent these infections are important. Since adherence to treatments and prevention methods can prove difficult, new research that provides evidence for the effectiveness of easier or more efficient methods of treatment and prevention is particularly exciting.
Human papillomavirus (HPV) is one sexually transmitted disease that has been linked with the development of cancers in some people. Therefore, the development of an HPV vaccine in 2006 provided much-needed hope against a potentially deadly disease. The vaccine was initially developed as a 3-dose regimen for pre-teen female patients, but recent research has found the vaccine to be effective for female patients in more age ranges, as well as male patients.

This week we published coverage on research that shows that “girls and boys who start the HPV vaccine series between the ages of 9 and 14 [and who are not immunocompromised] need only two doses,” as opposed to the typical 3-dose regimen of the past. Indeed, the authors of the study state that, “Through 10 years of follow-up from clinical trials, no evidence of waning protection after a 3-dose series of HPV vaccine has been found. Because antibody kinetics are similar with 2-dose and 3-dose series, duration of protection is also expected to be long-lasting after a 2-dose series.”
The new, easier-to-adhere to 2-dose regimen may help increase disappointing vaccination rates for HPV.
"Although the vaccine has been available for nearly a decade, HPV vaccine uptake has been slow, with estimated national three-dose coverage of adolescent females about 40% and adolescent males about 22%," said Kelly Jamison, MPH, a research scientist and analyst at the Bureau of Sexually Transmitted Disease Control of the New York City Department of Health and Mental Hygiene, and colleagues in their presentation on the research.
To learn more about the 2-dose vs 3-dose HPV vaccine, click here

Want more information on this topic and the opportunity to ask questions of an expert? Register for a live, ACPE accredited webinar February 28th 8-9 PM EST at this link:
Big advances in treatment can